Drug intelligence / Profile preview

DA-5222-R3

Development stage: Unknown
Lead developer: Dong-A ST
Administration: Oral

Overview

DA-5222-R3 is an investigational drug being studied as part of a pharmacokinetic and safety comparison with other related formulations (DA-5222, DA-5222-R1, DA-5222-R2) in healthy adults. The drug is developed by Dong-A ST and is currently being tested in phase 1 crossover studies to evaluate its pharmacokinetic profile and safety when administered individually and in combination with related compounds. As of now, specific details about its mechanism of action, molecular target, clinical indication, or therapeutic class have not been disclosed in public registries or studies[1][3][5][7][9][10].

Other names: DA-5222-R3DA5222-R3DA 5222-R3

Beyond the preview

Go deeper on DA-5222-R3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-5222-R3.

Explore the full profile